U.S. Markets closed

Oramed Pharmaceuticals Inc. (ORMP)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
8.56-0.02 (-0.23%)
At close: 4:00PM EDT
People also watch
OHRPVBLTCNATCANFONTX
Full screen
Previous Close8.58
Open8.57
Bid8.25 x 400
Ask8.73 x 1800
Day's Range8.26 - 8.58
52 Week Range5.70 - 8.94
Volume18,816
Avg. Volume46,228
Market Cap114.03M
Beta1.09
PE Ratio (TTM)-9.03
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Oramed Pharmaceuticals, Inc. :ORMP-US: Earnings Analysis: Q3, 2017 By the Numbers : July 10, 2017
    Capital Cube11 days ago

    Oramed Pharmaceuticals, Inc. :ORMP-US: Earnings Analysis: Q3, 2017 By the Numbers : July 10, 2017

    Categories: Yahoo FinanceGet free summary analysis Oramed Pharmaceuticals, Inc. reports financial results for the quarter ended May 31, 2017. Highlights Summary numbers: Revenues of USD 0.62 million, Net Earnings of USD -1.97 million. Change in operating cash flow of -5.89% compared to same period last year is about the same as change in earnings, likely no significant ... Read more (Read more...)

  • Associated Press15 days ago

    Oramed reports 3Q loss

    On a per-share basis, the Jerusalem-based company said it had a loss of 15 cents. The drug maker posted revenue of $617,000 in the period. Oramed shares have risen 36 percent since the beginning of the ...

  • Oramed Pharmaceuticals, Inc. :ORMP-US: Earnings Analysis: Q2, 2017 By the Numbers : May 5, 2017
    Capital Cube3 months ago

    Oramed Pharmaceuticals, Inc. :ORMP-US: Earnings Analysis: Q2, 2017 By the Numbers : May 5, 2017

    Categories: Yahoo FinanceGet free summary analysis Oramed Pharmaceuticals, Inc. reports financial results for the quarter ended February 28, 2017. We analyze the earnings along side the following peers of Oramed Pharmaceuticals, Inc. – Novo Nordisk A/S Sponsored ADR Class B, Ultragenyx Pharmaceutical, Inc. and Lexicon Pharmaceuticals, Inc. (NVO-US, RARE-US and LXRX-US) that have also reported for this ... Read more (Read more...)